Insmed's (INSM) brensocatib offering, "likely to be among the strongest launches in 2025," will be driven by high patient and physician demand for the chronic lung disease treatment, RBC Capital Markets said Monday in a report.
The drug, which will likely be approved with a clean label by Aug. 12, may reach a peak sales opportunity of $8.2 billion for bronchiectasis treatment with $53 million in 2025 sales, the investment firm said.
The drug has potential beyond bronchiectasis with mid-2025 data on chronic rhinosinusitis without nasal polyps possibly offering a $1 billion market opportunity, while 2026 data from trials of hidradenitis suppurativa, a chronic skin conditions, may expand brensocatib into specialty dermatology, adding $300 million in sales, RBC said.
Mycobacterium avium complex lung disease treatment Arikayce is expected to generate $425 million in 2025 sales and may expand if a phase 3 trial is successful, driving revenue to $1 billion, RBC said.
RBC initiated coverage on Insmed with an outperform rating and a $100 price target.
Shares of the company fell 3% in recent Tuesday trading.
Price: 77.63, Change: -2.40, Percent Change: -3.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.